BNTXBioNTech SE

Nasdaq biontech.de


$ 97.90 $ -1.57 (-1.58 %)    

Monday, 10-Jun-2024 12:40:07 EDT
QQQ $ 464.70 $ 1.91 (0.41 %)
DIA $ 388.18 $ -0.17 (-0.04 %)
SPY $ 534.95 $ 1.70 (0.32 %)
TLT $ 90.90 $ -0.13 (-0.14 %)
GLD $ 213.90 $ 0.82 (0.38 %)
$ 100.34
$ 99.47
$ 97.82 x 200
$ 105.32 x 500
$ 97.50 - $ 99.47
$ 85.21 - $ 125.83
377,870
na
23.85M
$ 0.08
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 moderna-seeks-fda-approval-for-updated-covid-19-shot-for-upcoming-season

Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.

Core News & Articles

- Reuters

Core News & Articles

- Bloomberg

Core News & Articles

https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%...

Core News & Articles

- Bloomberg

Core News & Articles

- Reuters

 whats-going-on-with-novavax-stock

Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look...

Core News & Articles

- Reuters

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

Core News & Articles

https://www.youtube.com/watch?v=qCsEbq9SpsM 

Core News & Articles

- Reuters - Reuters 

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

Core News & Articles

Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT051172...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 biontech-and-cepi-expand-partnership-to-strengthen-africas-mrna-vaccine-ecosystem-cepi-to-fund-up-to-145m-to-support-biontech-in-broadening-the-scope-of-the-manufacturing-facility-in-kigali-rwanda

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRN...

 jim-cramer-celestica-makes-a-comeback-sell-this-movie-theater-stock

Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.